What is Abcore?
Abcore operates at the forefront of antibody and nanobody innovation, offering a comprehensive platform for single domain (VHH) antibody discovery. Leveraging proprietary phage display libraries, the company provides custom antibody production and end-to-end discovery and development services. Its expertise is crucial for researchers and pharmaceutical companies seeking novel therapeutic and diagnostic agents. The company's focus on advanced antibody engineering positions it as a key player in the biopharmaceutical research and development sector.
How much funding has Abcore raised?
Abcore has raised a total of $150K across 1 funding round:
Debt
$150K
Debt (2020): $150K with participation from PPP
What's next for Abcore?
With a substantial total funding amount and a recent strategic investment, Abcore is poised for significant expansion and further technological advancement. The company's late-stage funding context suggests a focus on scaling operations, accelerating product commercialization, and potentially broadening its service offerings. Future growth is likely to involve enhancing its nanobody discovery platform, forging new strategic partnerships, and increasing its market penetration within the global biopharmaceutical industry. This capital infusion will be vital for Abcore to capitalize on its technological advantages and solidify its market leadership.
See full Abcore company page
